summari host call sumant ramachandra
md phd bax chief scienc technolog offic discuss
compani innov strategi key pipelin product overal
believ robust near-term pipelin produc
number import launch late help
acceler sale growth highlight
follow key product launch pharmaceut
new product includ one
platform drive multi-year upgrad cycl
theranova dialyz us poc point care pd
periton dialysi system us acut therapi
launch late clinic nutrit clinimax clinolipid
launch us later nearli decad new
product new product launch expect
acceler sale compound-annual-growth-rate
rais price target base updat
equal weight ev/ebitda dcf analysi
replay call avail april dial-in
confer id
transcript call also avail contact offic
pharmaceut focu differenti gener inject
portfolio expans anticip new product
revenu busi driven launch new
molecul repres new product nearli half
product clari expect resolv
outstand warn letter wl work back
manufactur new product mostli use specialti care
set like icu includ anesthesia anti-infect
version pfe precedex im sale total product
prior bax launch suggest attract revenu opportun
especi suppli shortag market
anticip new molecul launch includ one that
uniqu format alreadi fda review manag
anticip captur fair share market
product launch target peak sale
better product premix hard packag slate
launch later would expect
cadenc new launch thu revenu growth acceler
pharmaceut contribut bax lrp growth target
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
adjust spin-off baxalta
compani data secur llc estim reuter
continu previou page
biosimilar opportun like busi develop see larg opportun
biosimilar market compani evalu best way approach market seem
lean toward busi develop rather build intern inorgan approach could minim
disrupt exit small molecul inject busi balanc increment burden
contract manufactur note alreadi fill finish manufactur capabl
medic deliveri md focu next-gener integr pump platform work
first integr pump platform consist lvp larg volum parenter syring pca
patient-control analges develop new pump platform progress well
expect launch new pump platform along pull-through sale relat dispos
set expect import contributor bax target new product revenu
see new pump platform multi-year growth driver plan global roll start
us canada recal launch new sigma spectrum pump us
infus pump revenu grew double-digit follow period addit
manag also highlight adjac opportun piva peripher iv access non-
invas real-tim monitor patient fluid statu current method guid fluid therapi invas
 cathet piva may address clinic need ad benefit advanc analyt
run piva clinic trial expect commerci launch
renal focu theranova dialyz poc pd start pivot poc pd studi
anticip complet trial submit fda approv later suggest launch like
poc system intend significantli reduc amount pd solut need
ship store patient instead allow concentr mix water creat
solut autom basi believ could signific benefit patient cost
reduct time theranova dialyz prepar de novo regulatori file
anticip launch us theranova help clear larg urem toxin
worsen inflamm that associ cardiovascular diseas patient end-stag renal
diseas current dialyt therapi effect remov larg urem toxin
poc pd studi bioequival endpoint call manag reveal
detail import studi post clinicaltri gov studi detail redact
specif studi follow-up period understand
primari endpoint intend establish autom product dianeal solut
home use concentr water equival bax current sold dianeal solut real-lif
studi conduct patient home addit gather data fda approv also leverag
studi experi help prepar poc pd eventu commerci launch studi
complet expect late fda applic device/drug combo evalu
cdrh center devic radiolog cder center drug evalu research
initi target market us poc pd condens system may offer signific benefit
ou region especi develop market
addit near-term pipelin opportun acut therapi continu plan launch
prismax crrt continu renal replac therapi system us later prismax
intend help simplifi workflow optim accuraci deliv crrt icu intens care
unit advanc surgeri compani highlight tisseel floseal platform line
extens clinic nutrit manag note pend new product launch year clinimax
clinolipid essenti decad new product us clinolipid iv feed alreadi
fda approv launch later
price target
price target base equal weight ev/ebtida dcf p/e/g risk
thesi includ unexpect competit headwind could slow restructur effort signific delay new
believ deliv guidanc acceler sale growth margin expans ep
growth
baxter global medic product compani focus hospit product renal compani
report sale billion ex-fx growth
